ArticleStrahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]2025
Intra-adaptational changes in online adaptive radiotherapy: from the ideal to the real dose.
Article in Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Development of CBCT-Guided Online Adaptive Radiotherapy.Cancers · 2026Review
- CBCT based online daily adaptive treatment improves target coverage with limited benefit for OAR protection in SBRT prostate cancer.Radiation oncology (London, England) · 2026Article
- Clinical experience with an online adaptive radiotherapy for prostate cancer: successful treatment time optimization.BMC cancer · 2026Article
- Daily online adaptation enhances target coverage in prostate cancer radiotherapy: a retrospective analysis.Frontiers in oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background and purposeOnline adaptive radiotherapy has demonstrated dosimetric benefits by accounting for interfractional organ variations. However, this study investigates the dosimetric impact of intra-adaptational anatomical changes that take place during the adaptation process.
methodsOur retrospective analysis was conducted on 155 fractions from 8 prostate cancer patients treated with adaptive radiotherapy using the Varian Ethos system (Varian, Palo Alto, California, USA). Various dose-volume metrics for the targets and organs at risk were assessed for (1) the non-adapted (an original plan on a pretreatment cone-beam CT [CBCT], acquired at the beginning of a treatment session), (2) the adapted (an adapted plan on a pretreatment CBCT), and (3) the delivered dose distributions (an adapted plan on a pre-irradiation CBCT acquired for patient position verification with recontoured organs).
resultsFor the target metrics, we quantitatively proved that the delivered dose distribution was still beneficial in comparison to the non-adapted one, despite the anatomical changes during the adaptation process. The bladder dose-volume metrics strongly depended on the bladder volume variations across the planning CT and both CBCTs, frequently showing improvement during the adaptation process as the bladder continued to fill. In contrast, no clear trend was observed for the rectum or posterior rectum wall metrics. In only a small fraction of sessions (up to 5% for most metrics) were the metric objectives not achieved with the delivered dose while they were achieved with the adapted one. Physiological reasons for these occurrences stemmed from meteorism occurring between pretreatment and pre-irradiation CBCTs.
conclusionThis study confirms that the dosimetric advantages of online adaptive radiotherapy persist in clinical practice, despite anatomical changes due to the time delay needed for the adaptation process.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.